文章摘要
张 成,秦 超,吴 杰,成 功,华立新.长链非编码RNA PCAT4在前列腺癌中的表达及意义[J].南京医科大学学报,2017,(6):669~673,702
长链非编码RNA PCAT4在前列腺癌中的表达及意义
Expression and clinical significance of long non-coding RNA PCAT4 in prostate cancer
投稿时间:2016-08-21  
DOI:10.7655/NYDXBNS20170604
中文关键词: 前列腺癌  长链非编码RNA  PCAT4
英文关键词: prostate cancer  long non-coding RNA  PCAT4
基金项目:江苏省自然科学基金(BK20141495)
作者单位
张 成 南京医科大学第一附属医院泌尿外科江苏 南京 210029 
秦 超 南京医科大学第一附属医院泌尿外科江苏 南京 210029 
吴 杰 南京医科大学第一附属医院泌尿外科江苏 南京 210029 
成 功 南京医科大学第一附属医院泌尿外科江苏 南京 210029 
华立新 南京医科大学第一附属医院泌尿外科江苏 南京 210029 
摘要点击次数: 357
全文下载次数: 488
中文摘要:
      目的:探讨长链非编码RNA前列腺癌相关转录因子4(prostate cancer associated transcript 4,PCAT4)在前列腺癌中的表达及意义。方法:采用real-time PCR(RT-PCR)分别检测48例前列腺癌组织及其对应癌旁组织、人前列腺癌细胞PC3、22RV1和前列腺正常肌成纤维基质细胞WPMY-1中PCAT4的相对表达量;分析前列腺组织PCAT4的表达水平与患者临床病理特征的关系;采用RNA干扰技术、CCK-8法和迁移实验检测PCAT4对前列腺癌细胞增殖及迁移能力的影响。结果:前列腺癌组织与癌旁组织PCAT4的相对表达量分别为6.15±1.58和1.77±0.65,两组相比差异有统计学意义(P<0.001);前列腺癌PC3、22RV1细胞PCAT4的相对表达量均高于前列腺正常肌成纤维基质细胞WPMY-1,差异均有统计学意义(P<0.05)。前列腺癌组织中PCAT4 高表达30例,低表达18 例。前列腺癌组织PCAT4表达水平与患者Gleason 评分、T分期相关(P均<0.05),与年龄、肿瘤大小、淋巴结转移和多发病灶等均无相关性(P均>0.05)。前列腺癌22RV1细胞转染PCAT4小干扰siRNA后,前列腺癌细胞增殖和迁移能力明显减弱(P均<0.05)。结论:PCAT4在前列腺癌中呈相对高表达,可能通过影响前列腺癌细胞增殖和迁移促进前列腺癌的发生发展,可作为潜在的前列腺癌诊断新指标和治疗新靶点。
英文摘要:
      Objective: To investigate the expression of long non-coding RNA(lncRNA) prostate cancer associated transcript 4(PCAT4) and its clinical significance in prostate cancer. Methods: Real-time-PCR method was used to determine the relative expre-ssion of PCAT4 in 48 cancer samples and corresponding paracancerous tissues from patients with prostate cancer, as well as prostate cancer cells PC3, 22RV1 and normal myofibroblast stromal cells WPMY-1. The relationship between the expression level of PCAT4 and the clinicopathological characteristics of patients with prostate cancer was analyzed. We detected the effects of PCAT4 on the cell proliferation and migration of prostate cancer cells by RNA interference, CCK-8 assay, and migration experiment. Results: The relative expression levels of PCAT4 in the prostate cancer tissues and adjacent tissues were 6.15±1.58 and 1.77±0.65, respectively (P<0.001), while the relative expression levels of PCAT4 in the prostate cancer cell line PC3 and 22RV1 were higher than that in WPMY-1. The high expression of PCAT4 in the prostate cancer tissues was found in 30 cases of 48 cases, and 18 cases were low expression. The relative expression level of PCAT4 in prostate cancer tissues was associated with Gleason score and T stage (both P<0.05), and was not associated with age, tumor size, lymph node metastasis and multiple lesions (all P>0.05). In addition, the siRNA-mediated knockdown of PCAT4 in PC3 and 22RV1 cell lines significantly decreased the ability of proliferation and migration (all P<0.05). Conclusion: The relative expression level of PCAT4 was elevated in prostate cancer. PCAT4 may promote the carcinogenesis and development of prostate cancer by affecting the proliferation and migration of prostate cancer cells, which can be used as a potential novel target for the diagnosis and treatment.
查看全文   查看/发表评论  下载PDF阅读器
关闭